Prospective Data Collection of Patients With Diffuse Parenchymal Lung Diseases

This study is currently recruiting participants. (see Contacts and Locations)

Verified November 2014 by Singapore General Hospital

Sponsor:

Information provided by (Responsible Party):

Singapore General Hospital

ClinicalTrials.gov Identifier:

NCT01600378

First received: May 15, 2012

Last updated: November 26, 2014

Last verified: November 2014

History of Changes

Purpose

The purpose of this study is to generate a prospective database of all patients evaluated for diffuse parenchymal lung diseases to provide much needed data on the various disease aetiologies, incidence and prevalence rates, clinical and radiological presentations, pathologic correlations, disease progression and response to treatment, and final outcomes in this group of patients in Singapore.

Condition
Diffuse Parenchymal Lung Diseases


Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Prospective
Official Title:	Prospective Data Collection of Clinical, Pulmonary Function, Radiological, Bronchoscopic and Fibered Confocal Fluorescence Microscopy Imaging, and Pathological Characteristics in Patients With Diffuse Parenchymal Lung Diseases

Resource links provided by NLM:

Genetics Home Reference related topics: idiopathic pulmonary fibrosis pulmonary alveolar microlithiasis

MedlinePlus related topics: Interstitial Lung Diseases Lung Diseases

Genetic and Rare Diseases Information Center resources: Idiopathic Pulmonary Fibrosis Usual Interstitial Pneumonia

U.S. FDA Resources

Further study details as provided by Singapore General Hospital:

Primary Outcome Measures:

Final diagnoses of patients presenting with diffuse parenchymal lung disease after complete evaluation [ Time Frame: 3 months ] [ Designated as safety issue: No ]


Estimated Enrollment:	500
Study Start Date:	May 2012
Estimated Study Completion Date:	April 2022
Estimated Primary Completion Date:	April 2022 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	21 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients evaluated for diffuse parenchymal lung diseases

Criteria

Inclusion Criteria:

All patients 21 years old and older diagnosed with suspected diffuse parenchymal lung disease (multi-lobar pulmonary infiltrates)

Exclusion Criteria:

None

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01600378

Contacts


Contact: Su Ying Low, BMBCh	+65 63214700	low.su.ying@sgh.com.sg

Locations


Singapore
Singapore General Hospital	Recruiting
Singapore, Singapore, 169608
Contact: Su Ying Low, BMBCh +65 3214700 low.su.ying@sgh.com.sg
Principal Investigator: Su Ying Low, BMBCh

Sponsors and Collaborators

Singapore General Hospital

Investigators


Principal Investigator:	Su Ying Low, BMBCh	Singapore General Hospital

More Information

Publications:

American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304. Review. Erratum in: Am J Respir Crit Care Med2002 Aug 1;166(3):426.

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.


Responsible Party:	Singapore General Hospital
ClinicalTrials.gov Identifier:	NCT01600378 History of Changes
Other Study ID Numbers:	2012/245/Cilddatabase
Study First Received:	May 15, 2012
Last Updated:	November 26, 2014
Health Authority:	Singapore: Domain Specific Review Boards

Keywords provided by Singapore General Hospital:


diffuse parenchymal lung disease interstitial lung disease idiopathic pulmonary fibrosis

Additional relevant MeSH terms:


Lung Diseases Lung Diseases, Interstitial Respiratory Tract Diseases

ClinicalTrials.gov processed this record on March 01, 2015

To Top